THDB: The winter insulin injection has obtained an overseas drug registration certificate
THDB recently obtained the product registration certificate for insulin aspart injection issued by the Indonesian Food and Drug Authority, with registration number DKI2570600143A1. This medication is a rapid-acting insulin primarily used to control postprandial blood sugar levels. The acquisition of this registration certificate will help THDB expand its international market, enhance its brand image, and strengthen its competitiveness in emerging markets
According to the Zhitong Finance APP, Tonghua Dongbao (600867.SH) announced that the company recently received the drug registration certificate for insulin aspart injection issued by the National Agency of Drug and Food Control of the Republic of Indonesia (Registration No.: DKI2570600143A1).
Insulin aspart injection is a rapid-acting insulin analog that takes effect 10-20 minutes after subcutaneous injection, with a duration of action of 3-5 hours, primarily controlling postprandial blood sugar. Insulin aspart is typically administered immediately before meals, and if necessary, can also be given immediately after meals. Insulin aspart has a quick onset of action and a relatively short duration, and is usually used in combination with long-acting insulin to achieve basal and postprandial blood sugar control for patients.
The issuance of the drug registration certificate for insulin aspart injection by the National Agency of Drug and Food Control of the Republic of Indonesia indicates that Tonghua Dongbao is authorized to sell insulin aspart injection in Indonesia, which is beneficial for enriching the company's international product line, enhancing brand image, expanding international business, accelerating the layout in emerging markets, and improving the company's competitiveness in the international market
